Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI376 in Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT04298879Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Apr 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of parsaclisib in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Innovent Biologics. Started Apr 2020; status: completed.
02
Drugs
parsaclisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04298879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04298879.